Search results for "hybrid compound"

showing 3 items of 3 documents

Structural phase transition in [(C2H5)4N][(CH3)4N]ZnCl4

2019

The hybrid crystal [(C2H5)4N][(CH3)4N]ZnCl4 was studied using several experimental methods. DSC studies revealed the first order phase transition to the high temperature phase at about 496 K. This phase transition was confirmed in dielectric studies. Optical observation revealed the domain structure appearance characteristic for that of the phase transition between tetragonal and orthorhombic phases. This phase transition shows a lowering of symmetry as in the case of bromide analogs. Additionally, the optical studies showed the appearance of a number of cracks in the sample and in some cases, the samples became milky after cooling from the high temperature to the room temperature phase.

010302 applied physicsPhase transitionStructural phaseMaterials scienceThermodynamics02 engineering and technology021001 nanoscience & nanotechnology01 natural sciencesCrystalPhase (matter)0103 physical sciencesGeneral Materials ScienceExperimental methods0210 nano-technologyOrganic–inorganic hybrid compounds; phase transitions; thermal and dielectric properties; ferroelastic domainsInstrumentationPhase Transitions
researchProduct

DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.

2019

Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, …

AntifungalCancer chemotherapymedicine.drug_classDrug Evaluation Preclinicaldihydrofolate reductase (DHFR) enzymePharmaceutical ScienceAntineoplastic AgentsComputational biologyReview01 natural scienceshybrid compoundsAnalytical Chemistrylcsh:QD241-44103 medical and health sciencesStructure-Activity RelationshipFolic Acidlcsh:Organic chemistryheterocyclic compoundsNeoplasmsDihydrofolate reductaseparasitic diseasesDrug DiscoverymedicineAnimalsHumansPhysical and Theoretical Chemistry030304 developmental biology0303 health sciencesHeterocyclic compoundbiology010405 organic chemistryDrug discoveryOrganic ChemistryDHFR inhibitors as anticancer agentSettore CHIM/08 - Chimica Farmaceutica0104 chemical sciencesDHFR drug discoveryTetrahydrofolate DehydrogenaseMechanism of actionChemistry (miscellaneous)Settore CHIM/03 - Chimica Generale E InorganicaDHFR inhibitors as anticancer agentsbiology.proteinMolecular MedicineFolic Acid Antagonistsmedicine.symptomMolecules (Basel, Switzerland)
researchProduct

DESIGN AND SYNTHESIS OF NEW QUINAZOLIN-4(3H)-ONE HYBRIDS AS DUAL INHIBITORS OF TUBULIN AND DIHYDROFOLATE REDUCTASE

New strategies are needed for fighting cancer with the goal to improve efficacy of anti-cancer therapy and to limit the onset of drug resistance. Indeed, cancer cells are able to set cellular mechanisms for survival and multiple pathways support their survival. The inhibition of one pathway may then result in the activation of an alternative pathway. One strategy useful for combatting this phenomenon is represented by multi-target drugs. Herein we will present our work aim at identifying new anticancer compounds, which combine dihydrofolate reductase (DHFR) properties with tubulin inhibition. DHFR is a key enzyme involved in the synthesis of raw material for cell proliferation and the inhib…

Heterocyclic compoundquinazolinoneanticancer activitytubulinhybrid compoundDHFRSettore CHIM/08 - Chimica FarmaceuticaDocking
researchProduct